RxDoctor Payments Data

Megan Drewieske

Nurse Practitioner · Green Bay, WINPI 1881133866

Payments from drug & device makers

$1,612in general payments, 2019–2025

Across 15 payments — averaging $107.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$321
  • Amgen$286
  • Insulet Corporation$266
  • Sanofi-aventis U.S. LLC$150
  • Sequel Med Tech, LLC$134
  • Xeris Pharmaceuticals, Inc.$128
  • plus $328 from 4 others

What the payments were for

  • Food & beverage$1,612100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,612 in reported general payments places this provider in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$159,356
Medicare patients
280
Services billed
8,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide225$362,567
TrulicityDulaglutide208$292,326
JardianceEmpagliflozin230$281,467
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog83$181,871
RybelsusSemaglutide95$170,720
MounjaroTirzepatide88$128,912
Tresiba Flextouch U-100Insulin Degludec142$125,671
Tresiba Flextouch U-200Insulin Degludec45$81,139
Fiasp FlextouchInsulin Aspart (Niacinamide)45$73,982
Lyumjev Kwikpen U-100Insulin Lispro-Aabc34$62,843
Lantus SolostarInsulin Glargine,hum.Rec.Anlog327$57,294
Humalog Kwikpen U-200Insulin Lispro18$51,953
Humalog Kwikpen U-100Insulin Lispro95$48,674
JanuviaSitagliptin Phosphate40$44,782
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog43$43,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6, Fiasp, Tresiba$321$592,249373 claims
Boehringer IngelheimJardiance$125$281,467230 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$150$35,51647 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →